VCLT vs XBI
Vanguard Long-Term Corporate Bond ETF vs SPDR S&P Biotech ETF
VCLT$70.39
Vanguard Long-Term Corporate Bond ETF
Long-term investment-grade corporate bonds.
Expense: 0.03%Yield: 5.84%
XBI$156.41
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.35%
Quick take
- • VCLT has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VCLT pays a higher dividend yield (5.84%).
Side-by-side metrics
| Metric | VCLT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 5.84% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $9.46B | $10.92B |
YTD return | -1.84% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.92 | 1.01 |
P/E ratio | — | — |
Last price | $70.39 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VCLT top holdings
Holdings data unavailable for VCLT.
XBI top holdings
Top holdings · XBI
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
Sector breakdown · XBI
Financial Services0.6%
Healthcare99.3%
About VCLT
VCLT (Vanguard Long-Term Corporate Bond ETF) is Long-term investment-grade corporate bonds. Managed by Vanguard, the fund carries $9.5B in assets under management, an expense ratio of 0.03%, a dividend yield of 5.84%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.